JP2003517829A5 - - Google Patents

Download PDF

Info

Publication number
JP2003517829A5
JP2003517829A5 JP2001546669A JP2001546669A JP2003517829A5 JP 2003517829 A5 JP2003517829 A5 JP 2003517829A5 JP 2001546669 A JP2001546669 A JP 2001546669A JP 2001546669 A JP2001546669 A JP 2001546669A JP 2003517829 A5 JP2003517829 A5 JP 2003517829A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antagonist
composition according
antibody
tweak receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001546669A
Other languages
English (en)
Japanese (ja)
Other versions
JP5148795B2 (ja
JP2003517829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/034755 external-priority patent/WO2001045730A2/en
Publication of JP2003517829A publication Critical patent/JP2003517829A/ja
Publication of JP2003517829A5 publication Critical patent/JP2003517829A5/ja
Application granted granted Critical
Publication of JP5148795B2 publication Critical patent/JP5148795B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001546669A 1999-12-20 2000-12-19 Ｔｗｅａｋ受容体 Expired - Fee Related JP5148795B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17287899P 1999-12-20 1999-12-20
US60/172,878 1999-12-20
US20334700P 2000-05-10 2000-05-10
US60/203,347 2000-05-10
PCT/US2000/034755 WO2001045730A2 (en) 1999-12-20 2000-12-19 Tweak receptor

Publications (3)

Publication Number Publication Date
JP2003517829A JP2003517829A (ja) 2003-06-03
JP2003517829A5 true JP2003517829A5 (https=) 2008-02-21
JP5148795B2 JP5148795B2 (ja) 2013-02-20

Family

ID=26868552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001546669A Expired - Fee Related JP5148795B2 (ja) 1999-12-20 2000-12-19 Ｔｗｅａｋ受容体

Country Status (9)

Country Link
US (1) US6824773B2 (https=)
EP (3) EP2298333A3 (https=)
JP (1) JP5148795B2 (https=)
AU (1) AU782067B2 (https=)
CA (1) CA2394015C (https=)
ES (1) ES2433011T3 (https=)
IL (1) IL149922A (https=)
NZ (1) NZ520171A (https=)
WO (1) WO2001045730A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
ATE487737T1 (de) * 1997-05-30 2010-11-15 Human Genome Sciences Inc 32 humane sekretierte proteine
US7001992B2 (en) * 1997-05-30 2006-02-21 Human Genome Sciences, Inc. Antibodies to secreted protein HEMCM42
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
AU5951901A (en) 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
AU8901901A (en) * 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
AU2002367318B2 (en) * 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
MX352180B (es) 2002-04-09 2017-11-13 Biogen Ma Inc El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
DE602004006871T2 (de) * 2003-07-24 2008-02-07 Amgen Inc., Thousand Oaks Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen
WO2005053728A2 (de) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
EP1709976A4 (en) * 2003-12-26 2007-10-17 Toshio Hirano EMT-INDUCING MEDIUM
ATE432353T1 (de) * 2004-07-27 2009-06-15 Riken Vektor zur expression von humaner n-deacetylase/n-sulfotransferase 2
DK1959981T3 (da) * 2005-02-03 2020-01-27 Coda Therapeutics Ltd Anti-connexin 43 forbindelser til behandling af kroniske sår
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
US20090068102A1 (en) * 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
EP1853312B1 (en) * 2005-03-07 2014-12-10 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
EP1764109A1 (de) * 2005-05-24 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den Tweak Rezeptor Fn14 binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
MEP35408A (en) 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP1876448A1 (en) * 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
US20070111326A1 (en) * 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
EP2545938A1 (en) 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies
CA2729351C (en) 2008-06-30 2017-01-24 University Of Pennsylvania Fn14/trail fusion proteins
WO2010085648A2 (en) * 2009-01-23 2010-07-29 Linda Burkly C Methods for reducing radiation-induced tissue damage
CA2748889A1 (en) * 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
US9068004B2 (en) 2010-02-04 2015-06-30 University Of Louisville Research Foundation, Inc. TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
MX359833B (es) * 2011-08-19 2018-10-12 Regeneron Pharma Anticuerpos anti-tie2 y usos de los mismos.
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
KR101843248B1 (ko) * 2015-03-17 2018-03-29 고려대학교 세종산학협력단 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물
MY204672A (en) * 2018-10-31 2024-09-09 Astellas Pharma Inc Anti-human fn14 antibody

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1984A (en) 1841-02-18 Machinery for trimming straw braid
US554806A (en) 1896-02-18 Filling and bunging apparatus
US815330A (en) 1903-06-15 1906-03-20 Thomas J Bull Lamp-rheostat.
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5202422A (en) 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1994000469A1 (en) 1992-06-26 1994-01-06 Immunex Corporation Novel tyrosine kinase
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
ATE250138T1 (de) * 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
US5674704A (en) 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US5880327A (en) 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
CZ297387B6 (cs) * 1996-08-07 2006-11-15 Biogen Idec Ma Inc. Sekvence DNA kódující ligand príbuzný TNF, polypeptid a zpusob jeho prípravy, protilátka reaktivní s polypeptidem a farmaceutická kompozice
CA2280231A1 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
ATE487737T1 (de) 1997-05-30 2010-11-15 Human Genome Sciences Inc 32 humane sekretierte proteine
AU7549498A (en) * 1997-06-03 1998-12-21 Protegene Inc. Human proteins having transmembrane domains and dnas encoding these prot eins
EP1021542B1 (en) 1997-10-10 2009-03-04 Genentech, Inc. Apo-3 ligand
EP1080194A2 (en) 1998-05-29 2001-03-07 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
EP1100869A4 (en) 1998-07-30 2005-04-27 Human Genome Sciences Inc 98 HUMAN SECRETED PROTEINS
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
ATE324444T1 (de) 1999-06-07 2006-05-15 Immunex Corp Tek-antagonisten
AU5951901A (en) 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
AU8901901A (en) 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background

Similar Documents

Publication Publication Date Title
JP2003517829A5 (https=)
RU2402567C2 (ru) Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2
US9782496B2 (en) Immunoconjugates for the treatment of tumours
JP5746006B2 (ja) キメラのコイルドコイル（二重コイル）分子を使用する方法
JP2004508828A (ja) 標的−特異的プロドラッグとしての使用のための抗体サイトカイン−サイトカインインヒビター（セレクトカイン）からの融合タンパク質
KR20050003400A (ko) 시토킨과 종양 표적화 단백질의 융합물
EA011992B1 (ru) Гибридный белок антитела l19 к фибронектину ed-b и интерлейкина 12
CN102470156A (zh) 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途
JP2015535523A (ja) アプロチニン由来ポリペプチド−抗体コンジュゲート
JP4823060B2 (ja) Ｔｗｅａｋ受容体のマルチマー化およびオリゴマー化可溶性断片に関する組成物および方法
ZA200508767B (en) Apparatus for cryogenic air distillation
TWI300414B (en) Modified peptide yy and conjugates thereof
TW201245221A (en) FGF based fibrin binding peptides
US20100068145A1 (en) Bispecific fusion protein having therapeutic and diagnostic potential
JP5981525B2 (ja) Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途
TW201809013A (zh) 用於藥物遞送之抗體融合蛋白
AU2016287787A1 (en) B1SP fusion protein therapeutics, methods, and uses
Potala et al. Modified DT–IL2 fusion toxin targeting uniquely IL2Rα expressing leukemia cell lines–Construction and characterization
TWI327149B (en) Peptides and related compounds having thrombopoietic activity
JP4020467B2 (ja) 細胞接着活性ペプチド
MXPA06000653A (en) Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor
HK1072443B (en) Immunoconjugates for the treatment of tumours